tirzepatide

Headlines · 2

1. Oct 8
   Hybio's HY3003 triple agonist gets FDA IND acceptance

   Hybio Pharmaceutical said it received an FDA acceptance notice for its investigational new drug application for HY3003 injection; human trials can begin if the FDA does not impose a hold within 30 days. The candidate is a weekly subcutaneous GLP-1R/GIPR/GCGR triple-receptor agonist discovered using the company's AI peptide-chip screening technology, aimed at weight loss and type 2 diabetes. Hybio says preclinical work showed better weight reduction than the marketed dual agonist tirzepatide, a company-reported comparison.

   36氪快讯 · 🔥 0
2. Oct 8
   Eli Lilly CEO: AI drug discovery still needs far more biology data

   In an interview on the Cheeky Pint podcast, Eli Lilly CEO David Ricks said the company's LillyPod biomedical supercomputer — 1,016 NVIDIA Blackwell Ultra GPUs on a DGX SuperPOD B300 architecture — is being used to train biomedical AI models for drug discovery and molecular design, and that Lilly and NVIDIA plan to invest up to $1 billion over five years in a joint AI innovation lab. Ricks estimated humans understand only 10–15% of biology and said coverage may need to exceed 50% before AI can reliably predict complex biological systems, proposing round-the-clock robotic labs to generate the missing data. He also said China now accounts for roughly 30% of global drug development pipelines, and argued for about 12 years of clinical data exclusivity on top of patents for drugs that complete Phase III trials.

   MIT科技评论中文 · 🔥 0

Experience and discussion from the community

Share my tirzepatide experienceAsk about tirzepatide